Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imidacloprid + permethrin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Imidacloprid + permethrin** is a veterinary pharmaceutical combination used topically as an ectoparasiticide, primarily in dogs. Imidacloprid is a neonicotinoid insecticide that acts as an agonist at nicotinic acetylcholine receptors in parasites, leading to paralysis and death by inhibiting cholinergic transmission. Permethrin is a synthetic pyrethroid that targets voltage-gated sodium channels in arthropods, causing hyperexcitability and death. The combination is synergistic: imidacloprid activates arthropod ganglia, increasing permethrin efficacy. The product is indicated for the prevention and treatment of flea infestations, biting lice, tick infestations, sand flies, mosquitoes, and stable flies in dogs. It provides both insecticidal and repellent (anti-feeding) efficacy, reducing the risk of pathogen transmission (e.g., ehrlichiosis, leishmaniasis), with effects lasting up to four weeks. It is for dermal (spot-on) administration and is not to be used on cats due to toxicity[2][3][1].
- Brand names
- Advantix
- Other names
- Advantix spot-onimidacloprid/permethrin combination
02
Targets
NaV (Voltage-gated sodium channels)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on imidacloprid + permethrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imidacloprid + permethrin.